



ICI PAKISTAN LTD.

ICI House, 5 West Wharf,
Karachi 74000

T +92 21 3231 3717-22
F +92 21 3231 1739
UAN 111 100 200

www.ici.com.pk

The General Manager
Pakistan Stock Exchange Limited
Stock Exchange Building,
Stock Exchange Road,
Karachi – 74000

Ref # ComSec/PSX/12/2017
March 3, 2017

Subject: Disclosure of Material Information

Dear Sir,

This is in furtherance to our letter Ref No. ComSec/PSX/21/2016 dated December 9, 2016.

In accordance with Sections 96 and 131 of the Securities Act, 2015 and Clause 5.19.13(c) of the Rule Book of the Pakistan Stock Exchange Limited, we hereby inform you that the Board of Directors of ICI Pakistan Limited (ICI) have approved the purchase of a manufacturing facility owned by Wyeth Pakistan Limited ('Wyeth'), located at S-33, Hawkes Bay Road, S.I.T.E. Karachi, along with the acquisition of i) Wyeth's products and registrations, namely: Entox-P; Lederplex; Lederrif; Mucaine; Nilstat; Tri-Hemic; and Wymox, and ii) products and registrations of Pfizer Pakistan Limited, namely: Citralka and Combatriin ("the Asset Purchase Transaction"), subject to all regulatory approvals.

In this regard the Board of Directors have further authorized finalization and execution (as necessary) of the definitive Transaction documents/agreement(s) including but not limited to the Asset Purchase Agreements, the Manufacturing Supply/Packaging Agreement(s) and all ancillary documents with Wyeth/Pfizer.

A disclosure form as required under S.R.O.143(1)/2012 dated December 5, 2012 read with Section 131 of the Securities Act, 2015 is also enclosed as **Annexure – 'A'**.

Sincerely,

Saima Kamila Khan
Company Secretary

cc: The Commissioner
Company Law Division, Securities & Exchange Commission of Pakistan
NIC Building, Jinnah Avenue, Islamabad.

The Commissioner
Securities Market Division, Securities & Exchange Commission of Pakistan
NIC Building, Jinnah Avenue, Islamabad.



Annexure – ‘A’

DISCLOSURE FORM

IN TERMS OF SECTIONS 96 AND 131 OF THE SECURITIES ACT, 2015

Name of Company:	ICI Pakistan Limited ICI House, 5 West Wharf, Karachi.
Date of Report:	March 3, 2017
Contact Information:	Saima Kamila Khan Company Secretary ICI House, 5 West Wharf, Karachi. Telephone Number: +9221-111-100-200 (Ext- 8114) Fax Number: +92 21 32312500

[X] Public disclosure of price sensitive / inside information, which directly concerns the listed securities.

Disclosure of price sensitive / inside information by listed company.

“In accordance with Sections 96 and 131 of the Securities Act, 2015 and Clause 5.19.13(c) of the Rule Book of the Pakistan Stock Exchange Limited, we hereby inform you that the Board of Directors of ICI Pakistan Limited (ICI) have approved the purchase of a manufacturing facility owned by Wyeth Pakistan Limited (‘Wyeth’), located at S-33, Hawkes Bay Road, S.I.T.E. Karachi, along with the acquisition of i) Wyeth’s products and registrations, namely: Entox-P; Lederplex; Lederrif; Mucaine; Nilstat; Tri-Hemic; and Wymox, and ii) products and registrations of Pfizer Pakistan Limited, namely: Citralka and Combatrin (“the Asset Purchase Transaction”), subject to all regulatory approvals.

In this regard the Board of Directors have further authorized finalization and execution (as necessary) of the definitive Transaction documents/agreement(s) including but not limited to the Asset Purchase Agreements, the Manufacturing Supply/Packaging Agreement(s) and all ancillary documents with Wyeth/Pfizer.”

The Company has duly caused this form / statement to be signed on its behalf by the undersigned hereunto duly authorized.

Sincerely,


Saima Kamila Khan
Company Secretary